Survodutide
WellnessAlso known as: BI 456906, Glucagon/GLP-1 Dual Agonist, Boehringer Ingelheim Obesity Peptide
Emerging ResearchWhat is Survodutide?
A once-weekly injectable dual agonist of the glucagon receptor and GLP-1 receptor, developed by Boehringer Ingelheim. Phase 2 data showed up to 18.7% body weight reduction, and Phase 3 SYNCHRONIZE-1 results (April 2026) showed 16.6% weight loss. Distinctively, survodutide is also being investigated for MASH (metabolic dysfunction-associated steatohepatitis) — where its glucagon component adds hepatic fat-burning effects beyond what GLP-1 alone achieves. Not yet FDA approved.
How it works
Activates both the GLP-1 receptor (appetite suppression, slowed gastric emptying, insulin secretion) and the glucagon receptor (increased hepatic fat oxidation, glycogenolysis, and energy expenditure) simultaneously. The glucagon receptor component is the key differentiator from semaglutide and tirzepatide — glucagon receptor activation in the liver directly enhances mitochondrial fat oxidation and reduces hepatic steatosis, making survodutide particularly interesting for MASH, where liver fat accumulation is the central pathology. The balance of GLP-1 vs glucagon agonism is tuned to minimize the hyperglycemic effects of pure glucagon activation while retaining the metabolic benefits.
What marketers claim
- ▸better than Ozempic with no side effects
- ▸cures fatty liver disease permanently
- ▸available now as a prescription
- ▸works on everyone regardless of diet
What evidence supports
- ✓Phase 2 trial (Lancet Diabetes Endocrinol, 2024): 387 participants, survodutide 4.8mg achieved mean weight loss of 18.7% (on-treatment data) vs 2.8% placebo at week 46
- ✓Phase 3 SYNCHRONIZE-1 (Boehringer Ingelheim, April 2026): 16.6% mean body weight reduction vs placebo — largest Phase 3 readout to date for glucagon/GLP-1 dual agonism
- ✓significant and dose-dependent reductions in systolic blood pressure observed across dose groups
- ✓strongest biopsy-proven MASH resolution in Phase 2 among dual agonists studied to date (vs survodutide, efinopegdutide, mazdutide, cotadutide)
- ✓not yet FDA or EMA approved — regulatory submission expected following Phase 3 completion
Research evidence
Key studies on Survodutide, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Finding: Mean body weight change of −14.9% (planned analysis) and −18.7% (on-treatment analysis) at week 46 with survodutide 4.8mg vs −2.8% placebo. Dose-dependent weight loss across all dose groups. Significant blood pressure reductions observed.
Limitation: Phase 2 dose-finding trial — not powered for definitive efficacy conclusions. Excluded patients with type 2 diabetes. Higher attrition at the highest dose due to GI side effects.
SYNCHRONIZE-1: Phase III trial of survodutide in adults with overweight or obesity
Finding: Top-line Phase 3 results (Boehringer Ingelheim, April 2026): survodutide achieved 16.6% mean body weight reduction vs placebo, with significant improvements in cardiometabolic markers. Full peer-reviewed publication pending.
Limitation: Top-line press release only — full dataset, subgroup analyses, and side effect profile not yet published in a peer-reviewed journal. Results should be interpreted with caution until full data is available.
Dual GLP-1–glucagon agonists in MASH: comparative Phase 2 biopsy-proven efficacy
Finding: A Lancet review comparing dual GLP-1/glucagon agonists (survodutide, efinopegdutide, mazdutide, cotadutide) found survodutide showed the strongest biopsy-proven MASH resolution signal in Phase 2, establishing it as the leading compound in this mechanistic class for hepatic disease.
Limitation: Cross-trial comparison, not a head-to-head randomized study. Patient populations, doses, and endpoints differed across trials. Phase 3 MASH data (LIVERAGE program) is ongoing.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Month 1–3
Dose escalation phase. GI side effects most likely during this period. Initial appetite suppression and modest early weight loss (typically 3–5%).
Month 3–6
Meaningful weight loss becomes apparent. Liver fat reductions are measurable by imaging in MASH patients. Blood pressure improvements begin to emerge.
Month 6–12
Phase 3 SYNCHRONIZE-1 ran to 52 weeks, with peak weight loss of 16.6% emerging over this period. MASH histological improvements (biopsy-confirmed resolution) take at least 48–72 weeks to assess.
After stopping
Weight regain expected, consistent with GLP-1 class drugs. Whether MASH histological improvements are durable after discontinuation is under active investigation.
Safety notes & concerns
Full safety guide →- ⚠survodutide is not FDA or EMA approved as of May 2026 — not available as a standard prescription
- ⚠GI side effects (nausea, vomiting, diarrhea) are consistent with GLP-1 class compounds and were reported in trials
- ⚠glucagon receptor activation can theoretically raise blood glucose — the dual balance in survodutide attempts to minimize this, but careful monitoring is needed in diabetes or pre-diabetes
- ⚠cardiovascular outcome data (CVOT) is not yet available
- ⚠long-term safety of chronic glucagon receptor agonism in humans is not yet established
- ⚠weight regain upon discontinuation is expected — consistent with all GLP-1 class therapies
Pairs well with
Use caution with
Frequently asked questions
How is survodutide different from semaglutide or tirzepatide?
Semaglutide targets only GLP-1 receptors. Tirzepatide targets GLP-1 and GIP receptors. Survodutide targets GLP-1 and glucagon receptors. The glucagon component is the unique element — it enhances hepatic fat oxidation and energy expenditure in a way GIP agonism does not. This makes survodutide particularly interesting for MASH (fatty liver disease) alongside obesity, where tirzepatide has less differentiation.
What is MASH and why does survodutide matter for it?
MASH (metabolic dysfunction-associated steatohepatitis) is a progressive liver disease caused by fat accumulation in the liver, leading to inflammation and fibrosis. It affects an estimated 34% of people with obesity. Currently, no widely available pharmacological treatment is approved in most markets. Survodutide's glucagon receptor component directly enhances hepatic fat oxidation — a mechanism well-suited to MASH — and Phase 2 biopsy data showed the strongest MASH resolution signal among dual agonists studied.
Is survodutide available now?
Not as a standard prescription as of May 2026. Phase 3 results were only reported in April 2026. Regulatory submission to the FDA and EMA is expected to follow Phase 3 completion. Availability will depend on regulatory review timelines, likely 2027 at the earliest if approved.
How does the glucagon component not cause high blood sugar?
Glucagon normally raises blood glucose by stimulating the liver to release stored glucose (glycogenolysis). In isolation, this would be problematic. Survodutide is designed so the GLP-1 receptor component provides compensating insulin secretion and appetite suppression. The balance between the two activities is carefully tuned — the goal is to get the hepatic fat-burning benefit of glucagon receptor activation while the GLP-1 side prevents net hyperglycemia. Clinical trials have so far demonstrated this balance holds in the doses studied.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Survodutide
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.